Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.
2015 ◽
Vol 33
(15_suppl)
◽
pp. e19036-e19036
Keyword(s):
Phase Ii
◽